REVOLUTION MEDICINES INC (RVMD) Stock Fundamental Analysis
USA - NASDAQ:RVMD - US76155X1000 - Common Stock
69.22 USD
+1.47 (+2.17%)
We assign a fundamental rating of 2 out of 10 to RVMD. RVMD was compared to 533 industry peers in the Biotechnology industry. RVMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RVMD does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
RVMD had negative earnings in the past year.
RVMD had a negative operating cash flow in the past year.
In the past 5 years RVMD always reported negative net income.
In the past 5 years RVMD always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -26.65%, RVMD is doing good in the industry, outperforming 70.92% of the companies in the same industry.
RVMD's Return On Equity of -37.58% is fine compared to the rest of the industry. RVMD outperforms 72.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.65% | ||
| ROE | -37.58% | ||
| ROIC | N/A |
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RVMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
RVMD has more shares outstanding than it did 1 year ago.
RVMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RVMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 9.96 indicates that RVMD is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 9.96, RVMD belongs to the best of the industry, outperforming 83.49% of the companies in the same industry.
A Debt/Equity ratio of 0.16 indicates that RVMD is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.16, RVMD is not doing good in the industry: 66.04% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.96 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
RVMD has a Current Ratio of 8.05. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.05, RVMD is doing good in the industry, outperforming 74.11% of the companies in the same industry.
RVMD has a Quick Ratio of 8.05. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.05, RVMD is doing good in the industry, outperforming 74.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.05 | ||
| Quick Ratio | 8.05 |
3. Growth
3.1 Past
The earnings per share for RVMD have decreased strongly by -44.01% in the last year.
RVMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-44.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.28%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 16.99% on average over the next years. This is quite good.
The Revenue is expected to grow by 453.31% on average over the next years. This is a very strong growth
EPS Next Y-53.26%
EPS Next 2Y-31.41%
EPS Next 3Y-18.87%
EPS Next 5Y16.99%
Revenue Next Year1200%
Revenue Next 2Y810.52%
Revenue Next 3Y729.67%
Revenue Next 5Y453.31%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
RVMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVMD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RVMD's earnings are expected to decrease with -18.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.41%
EPS Next 3Y-18.87%
5. Dividend
5.1 Amount
RVMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RVMD (11/17/2025, 12:09:06 PM)
69.22
+1.47 (+2.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners103.32%
Inst Owner Change1.39%
Ins Owners1.99%
Ins Owner Change-2.69%
Market Cap12.94B
Revenue(TTM)N/A
Net Income(TTM)-600.09M
Analysts86.92
Price Target79.11 (14.29%)
Short Float %10.63%
Short Ratio9.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.02%
Min EPS beat(2)-12.79%
Max EPS beat(2)-11.24%
EPS beat(4)0
Avg EPS beat(4)-9.21%
Min EPS beat(4)-12.79%
Max EPS beat(4)-1.54%
EPS beat(8)1
Avg EPS beat(8)-7.65%
EPS beat(12)4
Avg EPS beat(12)-2.45%
EPS beat(16)6
Avg EPS beat(16)-2.06%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.38%
PT rev (3m)7.04%
EPS NQ rev (1m)-2.96%
EPS NQ rev (3m)-7.51%
EPS NY rev (1m)-1.06%
EPS NY rev (3m)-17.38%
Revenue NQ rev (1m)48.36%
Revenue NQ rev (3m)14.1%
Revenue NY rev (1m)-7.7%
Revenue NY rev (3m)-53.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.1 | ||
| P/tB | 8.48 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.17
EYN/A
EPS(NY)-6.16
Fwd EYN/A
FCF(TTM)-4.16
FCFYN/A
OCF(TTM)-4.08
OCFYN/A
SpS0
BVpS8.54
TBVpS8.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.65% | ||
| ROE | -37.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 277.69% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.05 | ||
| Quick Ratio | 8.05 | ||
| Altman-Z | 9.96 |
F-Score1
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)158.77%
Cap/Depr(5y)142.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.28%
EPS Next Y-53.26%
EPS Next 2Y-31.41%
EPS Next 3Y-18.87%
EPS Next 5Y16.99%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1200%
Revenue Next 2Y810.52%
Revenue Next 3Y729.67%
Revenue Next 5Y453.31%
EBIT growth 1Y-41.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56.47%
EBIT Next 3Y-24.05%
EBIT Next 5Y4.63%
FCF growth 1Y-158.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.07%
OCF growth 3YN/A
OCF growth 5YN/A
REVOLUTION MEDICINES INC / RVMD FAQ
What is the ChartMill fundamental rating of REVOLUTION MEDICINES INC (RVMD) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RVMD.
Can you provide the valuation status for REVOLUTION MEDICINES INC?
ChartMill assigns a valuation rating of 0 / 10 to REVOLUTION MEDICINES INC (RVMD). This can be considered as Overvalued.
How profitable is REVOLUTION MEDICINES INC (RVMD) stock?
REVOLUTION MEDICINES INC (RVMD) has a profitability rating of 1 / 10.
Can you provide the financial health for RVMD stock?
The financial health rating of REVOLUTION MEDICINES INC (RVMD) is 5 / 10.
Can you provide the expected EPS growth for RVMD stock?
The Earnings per Share (EPS) of REVOLUTION MEDICINES INC (RVMD) is expected to decline by -53.26% in the next year.